Dr. John Buse takes a look at some of the concerns of diabetic patients regarding the current COVID-19 vaccines.
Exploring COVID-19 in Diabetes: A Look at Disease Management & Risk
Written by John Buse, M.D., Ph.D.
ReachMD Host
Exploring COVID-19 in Diabetes: A Look at Disease Management & Risk
It’s pretty clearly established that people with obesity and people with diabetes are at higher risk of poor outcomes in the setting of COVID-19. What isn’t quite as well-established is whether people with diabetes with excellent glycemic control, as reflected by a hemoglobin A1C less than seven percent is associated with excess risk outside of the risk associated with comorbidities like coexistent cardiovascular or renal disease. The bulk of the evidence suggests that there probably is some modest, inherent risk in the setting of diabetes. But certainly, there’s much less risk in the setting of well-controlled diabetes than poorly controlled diabetes.
How about the issue of the COVID-19 vaccine in the setting of diabetes? There is very little in the way of specific studies in sub-populations with diabetes, but a subgroup analysis from vaccine trials suggests that the vaccines perform equally well in people with diabetes and with obesity as they do in the general population.
My advice to patients with diabetes is to get the COVID-19 vaccine as soon as they can. I do think that the COVID-19 is a potentially life-threatening disease. There are concerns about persistent symptoms and poor physical functioning in patients who have COVID-19 infections. So not only is the threat of COVID-19 the risk of hospitalization, prolonged intensive care, or death; but the notion that somehow, COVID-19 may result in prolonged disturbing or disabling problems even in those with milder infection. So, for all these reasons, I think that patients with diabetes, or at risk for diabetes in the setting of overweight or obesity, should all be vaccinated against the SARS-CoV-2 virus as soon as possible.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Dr. John Buse takes a look at some of the concerns of diabetic patients regarding the current COVID-19 vaccines.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway
Evolving Our View of the Coagulation Cascade and Stroke Management
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
Beyond Longevity: Discussing TAVR Durability for Women & Patients With Small Annuli
Clinical Conundrums in ARIA: 1. Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?